Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
"docetaxel or paclitaxel" is not a single drug but refers to either docetaxel or paclitaxel, both of which are members of the taxane class of chemotherapy agents. These drugs disrupt microtubule dynamics, leading to cell cycle arrest at the G2/M phase and ultimately inducing apoptosis in cancer cells. Both are widely used in the treatment of various cancers, including breast, ovarian, prostate, lung, and gastric cancers. Paclitaxel was originally derived from the bark of the Western Yew tree and is considered a first-generation taxane; docetaxel is a semi-synthetic second-generation derivative. Both drugs can be administered alone or in combination with other chemotherapeutic agents[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on docetaxel or paclitaxel.